Ogdh Antibody

What are the main differences between polyclonal and monoclonal OGDH antibodies in research applications?

Polyclonal OGDH antibodies (such as 15212-1-AP) recognize multiple epitopes on the OGDH protein, providing robust signal amplification and higher sensitivity, particularly useful in applications like Western blot and immunohistochemistry where protein quantities may be limited . Conversely, monoclonal OGDH antibodies (like 66285-1-Ig or E1W8H) target a single epitope with high specificity, offering more consistent lot-to-lot reproducibility and reduced background interference .

Polyclonal antibodies typically show broader species cross-reactivity (as evidenced by products reacting with human, mouse, rat, and other species) , whereas monoclonal antibodies may have more limited but predictable species reactivity. For experiments requiring precise epitope recognition, monoclonal antibodies are preferred, while polyclonal antibodies are advantageous for initial protein detection and when working with potentially denatured proteins .

What are the optimal storage conditions for maintaining OGDH antibody integrity?

For long-term preservation of OGDH antibody activity, most manufacturers recommend storage at -20°C in a buffer containing a cryoprotectant such as glycerol (typically 50%) and a preservative like sodium azide (0.02-0.05%) . This formulation prevents freeze-thaw damage while inhibiting microbial growth. Most OGDH antibodies remain stable for at least one year when stored under these conditions .

For frequent use within short periods (up to one month), temporary storage at 4°C is acceptable but should be avoided for extended periods to prevent degradation . It's important to note that unnecessary freeze-thaw cycles significantly reduce antibody performance, so aliquoting larger volume antibodies before storage is recommended. Some manufacturers specifically indicate that aliquoting is unnecessary for -20°C storage of small volumes (such as 20μl sizes), which often contain stabilizers like BSA (0.1%) .

What are the recommended dilution ranges for OGDH antibody across different applications, and how should optimal concentrations be determined?

Recommended dilution ranges for OGDH antibodies vary significantly depending on the application, antibody formulation, and target tissue/cell type. Based on validated protocols, the following dilution ranges serve as starting points:

For antibody titration, researchers should begin with the manufacturer's recommended range and perform a dilution series experiment with relevant positive controls (such as mouse heart tissue, A549 cells, or human lung cancer tissue for OGDH) . The optimal concentration balances specific signal intensity against background, providing the highest signal-to-noise ratio. Different tissues and cell lines may require adjusted concentrations due to varying OGDH expression levels .

What positive controls are most reliable for validating OGDH antibody specificity?

Based on extensive validation studies, the following positive controls have demonstrated consistent OGDH detection and should be considered for antibody validation:

Tissues:

• Mouse heart tissue (highly recommended)

• Mouse liver tissue

• Mouse lung tissue

• Human lung cancer tissue (particularly for IHC applications)

• Rat heart tissue

• Human heart tissue

Cell lines:

• A549 cells (human lung adenocarcinoma)

• HeLa cells (human cervical cancer)

• HepG2 cells (human liver cancer)

• ROS1728 cells

For negative control validation, OGDH knockdown/knockout samples have been documented in at least 6 publications according to antibody validation data . When selecting controls, researchers should consider tissue-specific expression patterns and choose controls with verified OGDH expression levels. For cross-species studies, ensure the selected antibody has been validated for reactivity with the target species .

How can researchers optimize antigen retrieval for OGDH immunohistochemistry?

Successful OGDH immunohistochemistry depends significantly on effective antigen retrieval. For formalin-fixed paraffin-embedded (FFPE) tissues, heat-induced epitope retrieval (HIER) has shown superior results with OGDH antibodies. Based on validation data, two buffer systems have proven effective:

• Primary recommended method: TE buffer at pH 9.0 (Tris-EDTA)

  • This alkaline buffer system has demonstrated optimal retrieval of OGDH epitopes in human lung cancer tissue and other samples.

• Alternative method: Citrate buffer at pH 6.0

  • This may be used when TE buffer yields suboptimal results or for specific tissue types.

For protocol optimization, retrieval should be performed using standardized conditions (typically 95-100°C for 15-20 minutes) followed by cooling to room temperature. Comparison of both buffer systems is recommended during initial protocol setup, as tissue fixation variations can affect antigen accessibility. For tissues with high fat content (like brain tissue), longer retrieval times may be necessary to unmask OGDH epitopes effectively .

How do different splice variants of OGDH affect antibody recognition, and which epitopes should be targeted for isoform-specific detection?

OGDH has multiple isoforms resulting from alternative splicing, which can complicate antibody-based detection. According to background information from antibody manufacturers, OGDH has at least 3 documented isoforms . Antibody selection for isoform-specific detection requires careful consideration of epitope location:

• N-terminal targeting antibodies: Antibodies targeting amino acids 148-427 (such as the immunogen used for some polyclonal antibodies) recognize regions that may be conserved across isoforms .

• C-terminal targeting antibodies: Antibodies targeting the C-terminal region (amino acids 700-1000) may provide better isoform discrimination as this region often contains unique sequences across splice variants .

For researchers specifically interested in distinguishing OGDH isoforms, Western blotting with antibodies targeting different epitopes is recommended, followed by mass spectrometry validation. When ordering custom antibodies, researchers should align isoform sequences to identify unique regions for epitope selection. Notably, the observed molecular weight of OGDH is consistently reported as approximately 110-116 kDa across multiple antibody validations, suggesting that the predominant isoform in most tissues maintains similar size characteristics .

What are the critical considerations when designing co-immunoprecipitation experiments to study OGDH protein-protein interactions?

Co-immunoprecipitation (Co-IP) of OGDH requires careful planning due to several factors specific to this mitochondrial protein:

• Antibody selection: Only certain antibodies have been validated for IP/Co-IP applications (with limited publications cited) . For example, the Cell Signaling Technology antibody (#13407) is recommended for IP at 1:50 dilution .

• Subcellular fraction considerations: Since OGDH functions primarily in mitochondria but has also been detected in nuclear fractions associated with histone modifications , researchers must decide whether to use whole cell lysates or purified mitochondrial/nuclear fractions based on their experimental objectives.

• Buffer optimization: For OGDH Co-IP, buffers containing mild detergents (0.5-1% NP-40 or Triton X-100) are recommended to maintain protein-protein interactions within the OGDH complex, particularly with DLST (dihydrolipoyllysine-residue succinyltransferase) and DLD (dihydrolipoyl dehydrogenase) components.

• Crosslinking considerations: Due to the transient nature of some OGDH interactions, particularly with metabolic enzymes, crosslinking with formaldehyde (0.1-0.5%) or DSP (dithiobis(succinimidyl propionate)) prior to lysis may improve co-precipitation efficiency.

• Controls: Both input controls and IgG negative controls are essential, along with verification of precipitated proteins by western blotting using alternative OGDH antibodies targeting different epitopes .

What experimental approaches can resolve discrepancies in OGDH antibody labeling patterns between mitochondrial and nuclear compartments?

Recent research has identified dual localization of OGDH in both mitochondrial and nuclear compartments, presenting challenges for accurate interpretation of immunolabeling results . To resolve potential discrepancies:

• Subcellular fractionation validation: Perform Western blotting on purified mitochondrial and nuclear fractions using OGDH antibodies alongside compartment-specific markers (VDAC/COX IV for mitochondria; Lamin B/Histone H3 for nucleus) to confirm specificity.

• Super-resolution microscopy: Conventional fluorescence microscopy may not clearly distinguish between mitochondrial and perinuclear OGDH signals. Super-resolution techniques (STED, STORM) provide ~20-50 nm resolution, sufficient to differentiate these compartments.

• Co-labeling strategies: For immunofluorescence studies, triple labeling with OGDH antibody, mitochondrial markers (MitoTracker or TOMM20), and nuclear stains (DAPI) allows precise localization assessment.

• Epitope mapping: Different antibodies targeting distinct OGDH epitopes may show varied nuclear vs. mitochondrial labeling, potentially reflecting conformational differences or protein interactions that mask certain epitopes in specific compartments.

• Proximity ligation assay (PLA): For validating specific nuclear interactions (such as OGDH-KAT2A), PLA provides sensitive detection of protein-protein interactions with spatial resolution, helping confirm the presence of functional OGDH in the nucleus versus potential artifacts .

How can researchers address non-specific binding issues with OGDH antibodies in Western blotting applications?

Non-specific binding in Western blotting with OGDH antibodies can manifest as multiple bands or background smearing. Several methodological approaches can mitigate these issues:

What strategies can improve OGDH signal detection in immunofluorescence applications with high autofluorescence tissues?

Detecting specific OGDH signals in tissues with high autofluorescence (particularly in mitochondria-rich tissues like heart, liver, and brain) presents significant challenges:

• Autofluorescence quenching: Pretreatment of sections with Sudan Black B (0.1-0.3% in 70% ethanol) for 10-20 minutes before antibody incubation effectively reduces endogenous fluorescence from lipofuscin and other autofluorescent components.

• Spectral unmixing: When using confocal microscopy, spectral unmixing algorithms can computationally separate OGDH-specific signals from tissue autofluorescence patterns.

• Alternative fluorophore selection: For OGDH detection in highly autofluorescent tissues, far-red fluorophores (Alexa Fluor 647 or similar) have demonstrated superior signal-to-noise ratios compared to green or red fluorophores.

• Signal amplification methods: For tissues with low OGDH expression, tyramide signal amplification (TSA) can enhance detection sensitivity by 10-50 fold while maintaining specificity, allowing more dilute antibody usage (1:500-1:1000) to reduce background .

• Optimized fixation protocols: Brief fixation (4% PFA for 10-15 minutes rather than overnight) better preserves OGDH antigenicity while reducing autofluorescence in most tissues. This approach has shown good results with both polyclonal and monoclonal OGDH antibodies in cell lines like A549, HeLa, and HepG2 .

How should contradictory results between different OGDH antibodies be interpreted and reconciled?

When different OGDH antibodies yield contradictory results, a systematic analytical approach can help reconcile discrepancies:

• Epitope mapping analysis: Compare the immunogen sequences of contradicting antibodies. Discrepancies may arise when antibodies target different domains of OGDH (N-terminal vs. C-terminal) . Antibodies recognizing amino acids 148-427 may detect different epitopes than those targeting amino acids 700-1000.

• Isoform-specific recognition: Contradictory results may reflect detection of different OGDH isoforms. Western blotting with both antibodies on the same samples, combined with mass spectrometry analysis of the detected bands, can identify whether isoform differences explain the discrepancies.

• Cross-reactivity assessment: Some antibodies may cross-react with related family members, particularly OGDHL (OGDH-like), which shares significant sequence homology. Testing the antibodies on OGDH knockout samples helps determine specificity.

• Application-specific performance: Antibodies performing well in Western blotting may fail in immunohistochemistry due to epitope masking or fixation sensitivity. Evaluating each antibody across multiple applications with appropriate positive controls helps identify application-specific limitations .

• Validation with orthogonal methods: For definitive resolution, orthogonal techniques (such as mass spectrometry, RNA-seq correlation, or CRISPR-Cas9 knockout validation) should complement antibody-based detection. Publications citing OGDH knockdown/knockout validation can provide valuable reference points for antibody specificity assessment .

What emerging applications are being developed for OGDH antibodies in metabolic disease research?

OGDH antibodies are increasingly employed in innovative research applications exploring metabolic dysfunction:

• Metabolic flux analysis: OGDH antibodies are being used to monitor dynamic changes in TCA cycle enzyme levels in response to metabolic challenges. Quantitative immunohistochemistry and immunofluorescence approaches allow researchers to correlate OGDH protein levels with metabolite measurements across different cellular compartments.

• Post-translational modification mapping: Recent studies suggest OGDH activity is regulated through various post-translational modifications. Modification-specific antibodies (targeting phosphorylated, succinylated, or acetylated OGDH) are being developed to map how these modifications affect enzyme function in metabolic disorders.

• Single-cell protein analysis: Emerging applications of OGDH antibodies in mass cytometry (CyTOF) and imaging mass cytometry enable researchers to quantify OGDH expression at the single-cell level within heterogeneous tissues, revealing metabolic heterogeneity relevant to diseases like diabetes, neurodegeneration, and cancer.

• Proximity-based interaction screening: OGDH antibodies coupled with BioID or APEX2 proximity labeling systems are being used to catalog the dynamic OGDH interactome under different metabolic states, expanding our understanding beyond the canonical OGDH complex interactions .

• In vivo metabolic imaging: Development of OGDH antibody fragments (Fabs, nanobodies) conjugated to near-infrared fluorophores enables real-time imaging of TCA cycle enzyme dynamics in disease models, potentially allowing non-invasive monitoring of metabolic adaptations during disease progression.

What methodological approaches can effectively address the challenges of detecting nuclear OGDH populations with current antibodies?

The recent discovery of nuclear OGDH pools requires specialized methodological approaches for reliable detection:

• Epitope accessibility enhancement: For detection of nuclear OGDH, modified fixation and permeabilization protocols using methanol/acetone fixation (10 minutes at -20°C) followed by 0.5% Triton X-100 treatment significantly improves nuclear epitope accessibility compared to standard formaldehyde fixation.

• Dual antibody validation approach: Combining antibodies targeting different OGDH epitopes (N-terminal and C-terminal) in sequential or simultaneous detection schemes can confirm authentic nuclear signals versus artifacts. True nuclear OGDH should be detected by antibodies targeting multiple distinct epitopes.

• Chromatin fractionation techniques: Standard nuclear isolation protocols may not effectively separate chromatin-bound OGDH from soluble nuclear proteins. Modified chromatin fractionation protocols with micrococcal nuclease digestion better preserve and isolate chromatin-associated OGDH for immunoblotting analysis.

• Super-resolution co-localization: STED or STORM microscopy combined with chromatin markers (like H3K27Ac) and specific transcription factor antibodies (such as KAT2A) provides spatial resolution below 50nm, sufficient to confirm genuine association of OGDH with specific chromatin regions versus non-specific nuclear signals.

• Live-cell tracking approaches: Expression of OGDH-HaloTag fusion proteins combined with specific antibody fragment detection systems enables dynamic tracking of OGDH translocation between mitochondrial and nuclear compartments in response to metabolic signals, complementing fixed-cell antibody studies.

How might advanced multiplexing techniques with OGDH antibodies reveal new insights into metabolic regulation at the tissue level?

Advanced multiplexing approaches using OGDH antibodies in conjunction with other metabolic markers enable systems-level analysis of metabolic regulation:

• Cyclic immunofluorescence (CycIF): Sequential staining-imaging-bleaching cycles with OGDH antibodies combined with up to 30-40 other metabolic enzymes, signaling proteins, and cell-type markers on the same tissue section reveals coordinated metabolic adaptations across heterogeneous cell populations.

• Multiplex immunohistochemistry with spectral unmixing: Combining OGDH antibodies with antibodies against other TCA cycle components (IDH, SDH, FH) and regulatory proteins using distinct chromogens or fluorophores allows visualization of the complete metabolic pathway architecture in tissue contexts.

• Mass spectrometry imaging with antibody-conjugated metal tags: Mass cytometry techniques (IMC, MIBI-TOF) using OGDH antibodies conjugated to rare earth metals enables simultaneous detection of dozens of proteins on tissue sections at subcellular resolution, correlating OGDH distribution with metabolic and signaling states.

• Spatial transcriptomics correlation: Combined OGDH immunostaining with spatial transcriptomics on serial sections creates integrated protein-transcript maps, revealing post-transcriptional regulation of OGDH across different microenvironments.

• Multi-scale imaging approaches: Correlative light and electron microscopy using OGDH antibody labeling bridges the resolution gap between fluorescence microscopy and ultrastructural analysis, precisely localizing OGDH within mitochondrial compartments and at sites of mitochondria-nucleus contact.